Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Now the falcon hears the falconer's all..."
You still using that broken keyboard? :>)
FFS’ assumption money lost, meaning shares sold reply to J.L. Don’t get me wrong I trade 2 to 3 thousand AMRN shares. I would have sold on this last peak, but used FFS chart from March 3 his premiss straight up and decided to Hold them. He was totally wrong as usual. Next time I go with my gut feeling. So now I wait now missing a chance for a nice buy back. It’s fun to take a gamble.
This is a silly statement, no money lost! Only an idiot or a short would sell!
I have better advise if your Amarin shares are dropping!
Stock-Market-Downer
Like your predictions. Which are wrong most of the time!
You had a different outlook 3 weeks ago.
Straight up Arrow for Amarin. Totally wrong!
Review your post 179108
You had a different outlook 3 weeks ago.
Straight up Arrow for Amarin. Totally wrong!
Review your post 179108
PS - It's been down hill since!
So what's your point a majority of my share are bought below $3. Amarin sales over the next couple of years are the most important factor. I will continue to purchase shares every month, been doing so for years.
Where is the Dow/NASDAQ going to be in three months?
Nonsense Reduce-It is an outcomes based trial. Not based on lipid values or MOA. The approval will be based Risk Reduction. Beside they are armed with MOA research of EPA already.
They don't even know the MO of Statins! Geez
The problem is greater than 50% of the people who have heart attacks, have normal lipids, why? Inflammation perhaps. V could be a great stand alone drug or preventative medicine for slowing or even reversing CVD.
I'm sure there are some thoughts about the possibility of a stand alone CVOT Amarin managment! Like jupiter probably base enrollment on inflammation markers rather than LDL-C levels.
Of course this will be kept under wraps until a design is well underway.
If true very good news!
I was hoping they would have filed before end of February, so if we don't get a priority review we are looking at 2020 to begin serious marketing.
The good thing is Amarin growth will continue, so it's a good hold. It will be many years before Amarin's income caps off.
Well not to mention market turmoil. Things could get bad during the summer. The trade war POTUS started having a negative effect on the Auto Industry, bleeding into other areas. Trade deficit actually climmed over the last two years because of tax cut's. Trade deficit, using tariffs wrong approach to problem. Yet to be resolved. Amarin being a Biomed stock getting hit hard along with many other's ACAD down over a dollar. IBB is down.
North40000 regarding question. I really don't have an answer. Maybe just slow enrollment or they want give Vascepa more time to work which would be a good idea achieve better scans.
We have to wait and see the verdict on the VA research using Vascepa. Could be a an eye opener or nothing. Would be great if we see something positive, but so far nothing in researchers grasp.
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : November 30, 2021
VA-Trial
But once again the Ivy League researchers seem to fail to find the direct link to this ratio, the regulator of inflammation. It must be very obscure.
Well the best approach is a long term outlook, over short term price action. We have a game changer and sales will continue accelerate.
I don't think buyout mania will end, until Amarin has sNDA approval in hand!
If the market trades sideways over the summer Amarin EOY price action may be our best hope, to make any serious money.
Yes I would say this is the work of pro's vs retail.
Well you seem to be the one confused with Amarin price action! Seems to do the opposite of your TA prediction. At lease Clay trader knows the chart may give a clue to the next day's price action. He clearly states, he has no idea what really will happen!
The question should be - who's selling?
FFS as usual your TA prediction flopped, stick to Graphic Arts.
This is correct don't see this changing any time soon, at least until a CVOT trial is designed by Amarin as a stand alone treatment.
That's right I saw that $40 price too, a couple days ago. Perhaps was a mistake on Amazons part and they corrected it. Because I placed an order a couple of weeks ago and the pricing option only had Amazon pricing, so the new options where just added. Not sure why they did this, does not make sense unless Amazon option is going to be removed eventually.
Not quite accurate on pricing or logic. Amazon was the sole seller of PharmaEPA ' restore' recently added sellers the manufacturer and UK source it's not totally clear. I still recommend the product and take it. Soon be checking United Health in VI regarding off label then renew my prescription for Vascepa.
The product quality is very good. Amazon can and does undercut retail pricing. The pricing roughly varied from $21-$29 over the years.
Pricing from Amazon:
$47.63 New Ships from United Kingdom
$24.00 New Fulfillment by Amazon 'Engenius'
$18.00 New Amazon.com
A preservative.
Yes it has if you buy from Amazon $18.00, From UK $47.68 per carton.
I paid this much for 4 cartons last month
Order Summary
Item(s) Subtotal:
$99.96
Shipping & Handling:
$10.41
Total before tax:
$110.37
Estimated tax to be collected:
$0.00
Grand Total:
$110.37
Well in that sense he has no business discussing Triglycerides, LDL-C or Reduce-It results data.
I mentioned this before, I prefer to here details from a Medical Professional i.e. Cardiologist who is well versed in the language of CVD.
My thought's too. Like weight data, EPA levels hidden in the background. Maybe they see an opportunity to file a few more patents.
Thanks..nothing else makes any sense here. This puppy should be gaining ground.
Thanks! great video! Post the link to Matthew Herper.
But this Cardiologist seems to think this is only Triglyceride lowering type drug.
Exactly...in fact from Vascepahcp.com
Robust CV risk reduction independent of TG levels1
Reduction in CV events was similar for patients with TG levels above and below 150 mg/dL
REDUCE-IT was a clinical outcomes trial, not a TG-lowering trial
Median percent change in TG for VASCEPA 4 g/d compared to placebo was -19.7%. Median percent change in LDL-C for VASCEPA 4 g/d compared to placebo was -6.6%
VASCEPA has multiple effects that extend beyond lipid-level modification including anti-thrombotic effects, antiplatelet or anticoagulant effects, membrane-stabilizing effects, effects on stabilization and/or regression of coronary plaque and inflammation reduction3
If Cardiologist's want's to go down the diet road. They should recommend a Japanese diet hands down, over the Mediterranean diet.
Since the Japanese have the lowest incident of CVD.
The fact is, the focus is and has been on single lipid, a fools folly when it comes to CVD.
Maybe these Cardiologist's aren't so smart. We have been through AHA and ACC and not a mention of EPA/AA ratios. This is partly John Thero's fault he never really talks about it either in his presentations. By this time it should be a household word, at least when the Cardiologists are having a conversation Reduce-It and Vascepa.
Did they perform AA/EPA ratio lab test in the Reduce-It trial? I would expect to see a graph RRR vs AA/EPA some where in one of the posters.
Yes a modest result would be good. If they want to market EPANOVA maybe they could work out an license agreement. :>)
But we have to start a campaign, regarding corn oil placebo being an active ingredient in this trial, which raises AA levels. Certainly not benign.
Now would Matthew Herper be up to the job?
Yes I found it thanks! Looks like we can expect results in October or maybe before. Any interim revues on this trial?